Current Tumour Immunotherapy strategies and their molecular basis

Authors

  • Shruti Sridhar Student, Department of Biological Sciences, BITS Pilani KK Birla Goa Campus, Goa
  • Keyur P. Chine Student, Department of Biotechnology, IIT Roorkee, Roorkee, Uttarakhand

Abstract

Abstract

Studying cancer and devising techniques to combat the deadly disease has witnessed a paradigm shift, from conventional toxic treatments of radiation and chemotherapy, to a more specific, and biologically significant immunotherapy and molecular targeted therapy. This can be seen in the global immunotherapy market, which is dominated by North America region valued about $45.9 billion in 2017 that is estimated to reach about $115.9 billion by 2025, and is closely followed by Europe, holding the second highest position in global immunotherapy drugs market with 29.0 billion revenues in 2016. Having changed the outlook towards cancer - from looking at it as just a clump of “poorly developed” or “rogue cells” to understanding the tumour microenvironment and associating it to study the biology of cancer as a tissue, has paved the way for immuno-oncology. The era of molecular targeting with the use of therapeutic monoclonal antibodies and modified cells of the immune system to help the immune system itself to fight cancer has shown great promise. Here in this review we have studied the molecular basis of a variety of treatments to help us understand targeted therapies more comprehensively.

 

Keywords: CAR T cell therapy, Combination therapy, Immune checkpoint inhibitors, Immuno-oncology, T-cell mediated immunotherapy

 

Cite this Article

Shruti Sridhar, Keyur P. Chine. Current Tumour Immunotherapy Strategies and their Molecular Basis. Research & Reviews: Journal of Oncology and Hematology. 2020; 9(2): 1–18p.

Downloads

Published

2020-09-21

Issue

Vol. 9 No. 2 (2020)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.